Amgen vs Gilead Sciences
Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates HIV and liver disease treatments and has spent years trying to diversify into oncology. Both large-cap biotechs generate prodigious free cash flow and return capital aggressively, yet their pipeline profiles and therapeutic concentrations differ significantly. The Amgen vs Gilead Sciences breakdown shows investors how patent cliff exposure, pipeline depth, and capital allocation choices separate two cash-rich biotech giants navigating the next decade of drug approvals.
Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates...
Why It's Moving
AMGN Stock Warning: Why Analysts See -11% Downside Risk
- Wall Street Zen shifted AMGN from Buy to Hold on April 25, reflecting concerns over weakening momentum and pre-earnings downside risks that could pressure the stock lower.
- Analyst consensus leans Hold with some targets implying notable declines from current levels around $344, underscoring vulnerability as moving averages signal a bearish trend.
- $4.1M in insider disposals over the last 12 months, including a major sale by a top executive near $337, signals executives' reluctance to hold at recent prices.
GILD Stock Warning: Analysts Flag -9% Downside Risk Amid HIV Drug Setbacks
- RBC notes HIV drug persistence lags expectations, threatening long-term revenue assumptions and kicker potential.
- Zacks Research cuts Q1-Q4 FY2026 EPS estimates, heightening near-term misses against consensus.
- Assetmark lowers holdings as health-care stocks decline, spotlighting GILD's vulnerability in turbulent biotech environment.
AMGN Stock Warning: Why Analysts See -11% Downside Risk
- Wall Street Zen shifted AMGN from Buy to Hold on April 25, reflecting concerns over weakening momentum and pre-earnings downside risks that could pressure the stock lower.
- Analyst consensus leans Hold with some targets implying notable declines from current levels around $344, underscoring vulnerability as moving averages signal a bearish trend.
- $4.1M in insider disposals over the last 12 months, including a major sale by a top executive near $337, signals executives' reluctance to hold at recent prices.
GILD Stock Warning: Analysts Flag -9% Downside Risk Amid HIV Drug Setbacks
- RBC notes HIV drug persistence lags expectations, threatening long-term revenue assumptions and kicker potential.
- Zacks Research cuts Q1-Q4 FY2026 EPS estimates, heightening near-term misses against consensus.
- Assetmark lowers holdings as health-care stocks decline, spotlighting GILD's vulnerability in turbulent biotech environment.
Investment Analysis
Amgen
AMGN
Pros
- Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
- Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
- Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.
Considerations
- Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
- High R&D expenses pressure margins despite obesity drug progress in early stages.
- Regulatory delays in novel assets like MariTide expose pipeline execution risks.
Gilead Sciences
GILD
Pros
- Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
- Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
- Expanding oncology pipeline nears key regulatory milestones for sustained growth.
Considerations
- Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
- Recent insider sales signal potential short-term concerns over performance.
- Modest consensus price target implies limited near-term upside from current levels.
Amgen (AMGN) Next Earnings Date
Amgen's (AMGN) next earnings date is expected on April 29 or 30, 2026, after market close. This report will cover the first quarter of 2026 (Q1 2026). Consensus among sources points to late April, aligning with the company's historical quarterly pattern following the prior Q4 2025 release in early February 2026.
Gilead Sciences (GILD) Next Earnings Date
Gilead Sciences (GILD) is scheduled to report its next earnings on May 7, 2026, after market close, covering the first quarter of 2026. This follows the prior release on February 10, 2026, aligning with the company's typical quarterly cadence. Investors should anticipate a conference call shortly thereafter to discuss results.
Amgen (AMGN) Next Earnings Date
Amgen's (AMGN) next earnings date is expected on April 29 or 30, 2026, after market close. This report will cover the first quarter of 2026 (Q1 2026). Consensus among sources points to late April, aligning with the company's historical quarterly pattern following the prior Q4 2025 release in early February 2026.
Gilead Sciences (GILD) Next Earnings Date
Gilead Sciences (GILD) is scheduled to report its next earnings on May 7, 2026, after market close, covering the first quarter of 2026. This follows the prior release on February 10, 2026, aligning with the company's typical quarterly cadence. Investors should anticipate a conference call shortly thereafter to discuss results.
Buy AMGN or GILD in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
